Evaluation of clinical guideline and establishment of evidence for the diagnosis and treatment of primary hyperaldosteronism in Japan.
Phase 4
- Conditions
- Primary aldosteronism
- Registration Number
- JPRN-UMIN000008844
- Lead Sponsor
- ational Hospital Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2641
Inclusion Criteria
Not provided
Exclusion Criteria
1)pregnant patients 2)patients taking aldosterone antagonist within the last one month 3)patients with the following diseases: (1)secondary hypertension (renal hypertension,renovascular hypertension, primary aldosteronism, Cushing's syndrome, pheochromocytoma, etc) (2)patients whom the attending doctors decides not suitable for the entry because of the unstable stage of the following complications: coronary diseases, arrhythmia, severe valvular diseases, cerebrovascular diseases, acute and chronic renal failure (serum Cr higher than 3mg/dl), acute and chronic liver diseases 4) Patients whom the attending doctor decides not suitable for the entry of the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)Adherance of clinical guideline for PA 2)Establishment of standard medication in PA and Aldosterone-rerated hypertension.
- Secondary Outcome Measures
Name Time Method 1)Implementation rate of each diagnostic procedure 2)Successful rate of the localization 3) Comparison of the effects of medical treatments and surgical treatment